- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03706820
Exercise Hemodynamics in Patients With Pulmonary Fibrosis
Hemodynamic Study of the Pulmonary Circulation in Exercise in Patients With Pulmonary Fibrosis
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
Patients with fibrotic pulmonary disease of the above origin will undergo detailed assessment of functional status with the following examinations: pulmonary function tests, echocardiogram, 6 minute exercise test, cardiopulmonary exercise test (in the absence of contra-indications) and finally right heart catheterization. Hemodynamic assessment will take place at rest and at exercise following the exercise protocol that was recommended by Herve et al (ERJ 2015) using a cycle ergometer at bedside.
The purposes of the study are:
- to evaluate the response of the hemodynamic parameters at exercise compared to the resting parameters in this patient group.
- to discriminate between precapillary from postcapillary etiology of pulmonary hypertension.
- to correlate non-invasive parameters of functional limitation with invasive hemodynamic parameters.
- to assess the prognostic role of exercise induced pulmonary hypertension in the specific patient group.
Undersøgelsestype
Tilmelding (Forventet)
Kontakter og lokationer
Studiesteder
-
-
Asvestochori
-
Thessaloniki, Asvestochori, Grækenland, 57010
- Rekruttering
- G.H. G. Papanikolaou
-
Kontakt:
- Evangelia S Panagiotidou, MD
- Telefonnummer: +306949139509
- E-mail: evangeliapanagiotidou@gmail.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- diagnosis of pulmonary fibrosis secondary to connective tissue disease, according to the American College of Rheumatology/European League Against Rheumatism (ACR-EULAR) revised classification criteria , or diagnosis of idiopathic fibrotic diffuse pulmonary disease according to American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines
- Forced vital capacity (FVC) ≥ 40 %
Exclusion Criteria:
- Presence of contra-indications to exercise tests, such as acute myocardial infarction, unstable angina, uncontrollable arrythmia or skeletal disease that limits the ability to exercise.
- History of pulmonary embolism during the year before enrollment
- Presence of severe valvular disease.
- Current treatment with vasoactive drugs of the pulmonary circulation
- Pulmonary wedge pressure (PAWP) at rest > 15 mmHg
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: Kun etui
- Tidsperspektiver: Fremadrettet
Kohorter og interventioner
Gruppe / kohorte |
|---|
|
normal rest and exercise hemodynamics
|
|
normal rest and abnormal exercise hemodynamics
|
|
resting pulmonary hypertension
|
|
abnormal wedge pressure at exercise
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in total pulmonary resistance (TPR) from rest to exercise
Tidsramme: 2nd minute,4th minute, 6th minute, 8th minute
|
The patient undergoes right heart catheterization and all hemodynamic variables are measured at rest and at exercise.
TPR is derived by the following equation : mean pulmonary artery pressure/ cardiac output (mPAP/CO).
TPR is measured at rest and at exercise following a specific protocol.
The measurements are made at rest, then at the sequential exercise steps of increasing work resistance.
|
2nd minute,4th minute, 6th minute, 8th minute
|
Samarbejdspartnere og efterforskere
Efterforskere
- Studiestol: Georgia G Pitsiou, MD, PhD, Aristotle University Of Thessaloniki
Publikationer og nyttige links
Generelle publikationer
- Kovacs G, Herve P, Barbera JA, Chaouat A, Chemla D, Condliffe R, Garcia G, Grunig E, Howard L, Humbert M, Lau E, Laveneziana P, Lewis GD, Naeije R, Peacock A, Rosenkranz S, Saggar R, Ulrich S, Vizza D, Vonk Noordegraaf A, Olschewski H. An official European Respiratory Society statement: pulmonary haemodynamics during exercise. Eur Respir J. 2017 Nov 22;50(5):1700578. doi: 10.1183/13993003.00578-2017. Print 2017 Nov. Erratum In: Eur Respir J. 2018 Jan 18;51(1):
- Herve P, Lau EM, Sitbon O, Savale L, Montani D, Godinas L, Lador F, Jais X, Parent F, Gunther S, Humbert M, Simonneau G, Chemla D. Criteria for diagnosis of exercise pulmonary hypertension. Eur Respir J. 2015 Sep;46(3):728-37. doi: 10.1183/09031936.00021915. Epub 2015 May 28.
- Panagiotidou E, Betaoutou A, Fouka E, Papakosta D, Chatzopoulos E, Sourla E, Markopoulou A, Kioumis I, Stanopoulos I, Pitsiou G. Phenotyping exercise limitation of patients with Interstitial Fibrosing Lung Disease: the importance of exercise hemodynamics. Pulmonology. 2022 May 11:S2531-0437(22)00105-2. doi: 10.1016/j.pulmoe.2022.03.012. Online ahead of print.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- MED-AUTH-3.1/02-05-2018
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Exercise Pulmonary Hypertension
-
VIVUS LLCIkke rekrutterer endnuPulmonal arteriel hypertension | Pulmonal arteriel hypertension (PAH) (WHO Group 1 PH) | Pulmonal arteriel hypertension (PAH) | Pulmonal arteriel hypertension WHO gruppe I | Pulmonal arteriel hypertension PAH
-
Inhibikase TherapeuticsIkke rekrutterer endnuPulmonal arteriel hypertension (PAH)
-
Philipps University MarburgMSD Sharp & Dohme GmbH, GermanyIkke rekrutterer endnu
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc...Ikke rekrutterer endnuPulmonal hypertension | Pulmonal arteriel hypertension (PAH)Forenede Stater
-
BayerAfsluttet
-
National Taiwan University Hospital Hsin-Chu BranchRekrutteringHypertension, essentiel | Hypertension, maskeretTaiwan
-
Rutgers, The State University of New JerseyRekrutteringPulmonal arteriel hypertension | Pulmonal hypertension | Pulmonal arteriel hypertension (PAH) (WHO Group 1 PH) | Pulmonal arteriel hypertension af medfødt hjertesygdom | Pulmonal arteriel hypertension forbundet med skistosomiasis (lidelse) | Pulmonal arteriel og kronisk tromboembolisk pulmonal... og andre forholdForenede Stater
-
BackBeat Medical IncIkke rekrutterer endnuHypertension, systolisk | Hypertension (HTN) | Hjertesvigt med bevaret ejektionsfraktion (HFpEF)Georgien
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI); University of MichiganIkke rekrutterer endnuPulmonal arteriel hypertension (PAH)Forenede Stater
-
University of Sao Paulo General HospitalRekrutteringPulmonal arteriel hypertension (PAH)Brasilien